Challenges in the clinical development of new antiepileptic drugs

摘要: Despite the current availability in market of over two dozen antiepileptic drugs (AEDs), about one third people with epilepsy fail to achieve complete freedom from seizures existing medications. Moreover, currently available AEDs have significant limitations terms safety, tolerability and propensity cause or be a target for clinically important adverse drug interactions. A review evidence shows that there are many misperceptions viability investing into new therapies epilepsy. In fact, clear incentives develop newer more efficacious Developing truly innovative requires shift paradigms discovery, which is already taking place by building on greatly expanded knowledge mechanisms involved epileptogenesis, seizure generation, spread development co-morbidities. AED can also benefit methodology applied clinical development, order address number ethical scientific concerns. As discussed this article, processes proof-of-concept-studies ambitious programs aimed at demonstrating antiepileptogenesis disease-modification, facilitated greater integration preclinical science, application acquired during decades controlled trials.